Sunshine Biopharma (SBFM) Net Cash Flow (2010 - 2026)

Sunshine Biopharma has reported Net Cash Flow for 17 years, with the latest figure at -$2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 40.27% year-over-year to -$2.2 million; the trailing twelve-month figure through Mar 2026 stood at -$2.0 million (up 76.39% YoY), and the FY2025 full-year result was -$1.4 million, up 74.49% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$2.2 million, down from -$941715.0 in the prior quarter.
• The five-year high for Net Cash Flow was $28.5 million in Q2 2022, with the low at -$19.0 million in Q4 2022.
• Historically, Net Cash Flow has averaged $260798.6 across 5 years, with a median of -$941715.0 in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 41959.55% — and 2024, when it tumbled 25270.25%.
• Sunshine Biopharma's Net Cash Flow stood at -$19.0 million in 2022, then surged by 84.23% to -$3.0 million in 2023, then jumped by 36.95% to -$1.9 million in 2024, then soared by 50.04% to -$941715.0 in 2025, then slumped by 131.13% to -$2.2 million in 2026.
• The last three Net Cash Flow figures came in at -$2.2 million (Q1 2026), -$941715.0 (Q4 2025), and -$770559.0 (Q3 2025), per Business Quant data.